Connect with us
Prague Gaming & TECH Summit 2025 (25-26 March)

Fintech PR

WuXi Biologics Reports Solid 2024 Interim Results

Published

on

wuxi-biologics-reports-solid-2024-interim-results

Revenue increased by 1.0% YoY to RMB 8,574.2 million
Non-COVID revenue grew by 7.7% YoY, with non-COVID late-phase & commercial manufacturing YoY growth of 11.7%
Added 61 new integrated projects, including 4 from late-phase and commercial stage
Client’s molecule recently acquired by MNC, highlighting a potential best-in-class CD3 asset utilizing three of our proprietary technology platforms
Total integrated projects of 742, one of the largest portfolios of complex biologics
Successful EMA inspections of 13 products and FDA inspections of 2 products in 1H24

HONG KONG, Aug. 21, 2024 /PRNewswire/ — WuXi Biologics (Cayman) Inc. (“WuXi Biologics” or “the Group”, stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for biologics discovery, development and manufacturing, is pleased to announce its unaudited interim results for the first half of 2024 (“Reporting Period”).

Financial Highlights

  • Revenue: The Group’s revenue for the Reporting Period matches that of the first half of 2023, totaling RMB 8,574.2 million, with a year-on-year (YoY) increase of 1.0%.  Excluding the COVID sales in the same period last year, the non-COVID revenue grew by 7.7%, and the non-COVID late-phase & commercial manufacturing revenue grew by 11.7% YoY. Key drivers supporting our base revenue growth include: (i) the successful execution of the Group’s “Follow and Win the Molecule” strategies, combined with our leading technology platforms, best-in-industry timeline and excellent execution track records; (ii) an expanded spectrum of services offered to the biologics industry, including fast-growing technology platforms such as antibody-drug conjugates (ADCs) and bispecific & multi-specifics; (iii) robust growth in pre-IND revenue, which more than offset the impact of significant Discovery Services deals in 1H 2023; and (iv) the utilization of newly expanded capacities, including the ramp-up of manufacturing sites in Europe and the U.S.
  • Gross Profit and Gross Profit Margin: IFRS gross profit was RMB3,350.0 million compared to RMB3,560.6 million in the same period last year. Adjusted gross profit was RMB3,811.2 million compared to RMB3,993.1 million in the same period last year. IFRS gross profit margin was 39.1% and adjusted gross profit margin was 44.4%. The decrease of gross profit margin was mainly due to the margin mix impact from the significant Discovery Services deals in 1H 2023, the slightly lower capacity utilization in China due to the COVID volume in the same period last year, the continued impact of the ramp-up of new manufacturing facilities in Ireland, Germany, and the U.S., all of which were partially offset by the efficiencies achieved from the WBS and other continuous improvement initiatives.
  • EBITDA and EBITDA Margin: EBITDA was RMB2,805.9 million compared to RMB3,230.6 million in the same period last year. Adjusted EBITDA was RMB3,570.4 million compared to RMB3,818.3 million in the same period last year. EBITDA margin was 32.7% and adjusted EBITDA margin was 41.6%.
  • Net Profit and Net Profit Attributable to Owners of the Company: IFRS net profit and net profit attributable to owners of the Company was RMB1,780.3 million and RMB1,499.1 million, respectively, representing a YoY decline of 23.9% and 33.9%. The decline was due to, among other factors, (i) an increase in selling, marketing and administrative expenses (“SG&A”) as the Group continues to invest in its geographic footprint, (ii) an increase in SG&A for WuXi XDC Cayman Inc., a non-wholly owned subsidiary of the Company, as a standalone listed company on the Main Board of The Stock Exchange of Hong Kong Limited (stock code: 2268), and (iii) an unmaterialized foreign exchange translation loss as a result of the depreciation of Euro against RMB year-to-date.
  • Adjusted Net Profit: Adjusted net profit was RMB2,544.8 million, down 13.0% YoY from a record-high base in 1H 2023.
  • Basic earnings per share (EPS): Basic EPS and adjusted basic EPS were RMB0.37 and RMB0.55, respectively.

Business Highlights

  • Amid a dynamic geopolitical landscape, the Group added 61 new integrated projects in 1H 2024, demonstrating the Company’s resilience and its ability to maintain growth. This, compared to 46 new projects added in 1H 2023, is one of our best 6-month periods for new project adds to date. Among the 61 newly added projects, 52 were from pre-IND, 5 from early-phase, 3 from late-phase, and 1 was from the commercial manufacturing phase. We believe that our robust business activities in the pre-IND stage signal early signs of a biotech funding recovery. During the Reporting Period, the Group continued to execute its “Win-the-Molecule” strategy, adding 9 post-IND projects, among which 4 are in the late-phase and commercial manufacturing stages. Since 2018, the Group has won 78 projects under the “Win-the-Molecule” initiative, with the winning formula centered on quality, speed, and advanced technological platforms.
  • The number of late-phase projects increased to 56, laying a strong foundation for future commercial manufacturing. The number of commercial manufacturing projects was 16, as we removed 8 COVID and 1 non-COVID dormant projects. The total number of integrated projects was 742, representing one of the largest portfolios of complex biologics, including bispecifics & multispecifics (123), ADCs (167), fusion proteins (76) and vaccines (23). Among the 123 bispecifics & multispecifics projects, WuXiBody™ and SDArBody™ accounted for nearly half, as both proprietary platforms continue to gain worldwide recognition.
  • As of June 30, 2024, total backlog reached US$20.1 billion, the same level as the first half of last year, including US$13.0 billion service backlog and US$7.1 billion upcoming potential milestone backlog. Backlog within 3 years exceeded US$3.6 billion, providing high visibility for near-term revenue opportunities.
  • The Group offers end-to-end CRDMO services through our global network. Our Ireland site is making great progress overall and is seeing significant commercial manufacturing demands from 2024 and onwards, with 2025 almost fully booked. MFG6.1 successfully completed its first PPQ campaign in 1H 2024, and MFG6.2 expansion is on track to be completed in the 4Q of 2024. MFG7 commenced commercial manufacturing, though there has been a slight delay in the ramp-up due to an operational issue during an engineering run. The site remains on track to reach its steady-state in 2026, serving a critical role in our “Global Dual Sourcing” network. For our Singapore site, construction work has commenced, initially to support XDC’s operation readiness in 2026. Design-work for WuXi Biologics facilities is still ongoing.
  • The Group’s unified and consistent quality system has been pivotal in driving our clients’ success and remains one of our key competitive advantages. A total of 21 inspections from the EMA and FDA were completed, with a 100% success rate in passing pre-approval inspections (PAIs). In 1Q 2024, EMA inspection of 13 products was successfully completed. In 2Q 2024, FDA inspection of 2 products was successfully completed.
  • Our industry-leading technology platforms span from discovery to development and manufacturing. Examples of discovery technologies include WuXiBody™ (for Bi-/Multi-specific antibody), T cell engager (TCE) platform, tumor associated antigens (TAA) mAb discovery, and single B cell technology. Examples of development technologies include WuXia™ (cell line development), WuXiDAR4™ (drug antibody ratio technology), and WuXiHigh™ (customized formulation strategies for high concentration drug products). Examples of manufacturing technologies include WuXiUI™ (ultra-intensified fed-batch manufacturing) and WuXiUP™ (ultra-high productivity continuous processing). WuXiUI™ is our next-gen manufacturing process that can increase titer by 3-6x with culture time comparable to traditional fed-batch processes, and is currently undergoing pilot runs. WuXiUP™ can increase titer by 5-15x, and resolve various quality issues, making it an ideal technology for unstable molecules, molecules that clients wish to increase titer of significantly, or molecules experiencing quality issues. Recently, our client, Curon Biopharmaceutical’s investigational B-cell depletion therapy CN201 was acquired by Merck & Co., Inc. CN201 utilizes 3 aforementioned proprietary technology platforms: WuXiBody™, TCE platform and WuXiUP™.
  • Our people are key assets of WuXi Biologics. As of June 30, 2024, the Group’s total staff comprised 12,435 employees, including approximately 4,200 scientists, and the total retention rate was approximately 94%. During 1H 2024, we announced the planned retirements of Dr. Weichang Zhou (former CTO), Mr. Peter Shen (CMO), and Dr. Jerry Xu (former CQO). We deeply appreciate their contributions to WuXi Biologics. The transition was seamless, with Dr. Sherry Gu (CTO), Dr. Wei Guo (Head of Global Manufacturing, effective August 2024), and Mr. Ing Hou Loh (Head of Global Quality) assuming these roles. With a deep bench of industry veterans who possess extensive domain expertise and proven leadership records, the Group is well-positioned to continue building a strong and sustainable organization for many decades to come.
  • WBS (WuXi Biologics Business System) is our lean operation and management system launched in 2021. During 1H 2024, by implementing approximately 60 Kaizen projects and events, the Group delivered Gross Profit Margin enhancement of roughly 100 basis points, along with significant business growth, inventory reduction, labor hour savings, and quality improvements to combat operation headwinds. Additionally, ESG Kaizen projects contributed to the Group’s ESG initiatives by achieving remarkable carbon emission reduction, material savings, waste reductions and more recycling, and water savings. We will continue to promote WBS as our lean culture to drive continuous improvements across all facets of our operations, to create better value for our clients, employees and partners
  • The Group has incorporated ESG as an essential part of its sustainable growth strategy. The Group’s ESG performance has been widely recognized by the industry and has been awarded an AAA rating from MSCI ESG Ratings, a Platinum Medal from EcoVadis, and was named an ESG Industry Top-Rated Company and an APAC Regional Top-Rated Company by Sustainalytics. In 2024, WuXi Biologics was included in S&P Global’s Sustainability Yearbook 2024 with a Top 1% S&P Global Corporate Sustainability Assessment (CSA) ranking and was named an Industry Mover.
  • The Group has always been committed to serving and contributing to the global healthcare community while adhering to the highest standards of regulatory compliance and operational excellence. The Group noted the introduction of the BIOSECURE Act in the U.S. Congress and subsequent amendments to it, including a proposed “grandfather” clause with transition period. The contents of the draft legislation remain subject to further review and modification as it moves through the legislative process and the legislative route also involves uncertainty. As a global biologics CRDMO platform, the Group does not have a human genomics business, nor does it collect human genomic data in any of its businesses around the world. The Group firmly believes that it has not, does not, and will not pose a security risk to the United States or any other countries. The Group will continue to closely monitor this process and remains committed to supporting its clients globally and to operating in accordance with the applicable laws and regulations of all jurisdictions where it has business operations. 

Management Comment

Dr. Chris Chen, CEO of WuXi Biologics, stated, “Amid a dynamic macroeconomic and geopolitical environment, our business has demonstrated strong resilience. This is attributed to our unique CRDMO business model which we believe is the most efficient for our industry, as well as the successful implementation of our ‘Follow and Win the Molecule’ strategies. In the first half of 2024, we added 61 new integrated projects, including 4 from late-phase and commercial stages. This is a strong testament to our clients’ endorsement of our exceptional execution and our technological leadership. Our client Curon’s molecule was recently acquired by Merck & Co., Inc., highlighting a potential best-in-class CD3 asset (CN201), which was discovered, developed, and manufactured using 3 of our proprietary technology platforms, WuXiBody™, TCE platform and WuXiUP™.” 

Dr. Chris Chen added, “Our business fundamentals remain strong. The Company’s unified and consistent quality systems, proprietary technology platforms, global talent pool – led by a seasoned management team and includes a strong technical team with over 4,200 scientists – and exceptional execution distinguish WuXi Biologics in our industry. We remain firmly committed to serving our global clients in the healthcare community and benefiting patients worldwide.”

Dr. Ge Li, Chairman of WuXi Biologics, concluded, “WuXi Biologics delivered solid business performance in the first half of 2024 despite an uncertain external environment and challenging comparisons year over year. Looking ahead, we will continue to adhere to our end-to-end CRDMO business model, expand our global presence and further improve our execution. We will continue to enhance our R&D and manufacturing efficiencies, deliver superior value to our partners, and benefit patients worldwide as an end-to-end, one-stop service provider for the biopharmaceutical industry. We remain dedicated to delivering groundbreaking therapies to patients and fulfilling our vision that ‘every drug can be made and every disease can be treated’.”

Key Financial Ratios
(For the Six Months Ended June 30)

Key Financial Ratio

1H 2024

1H 2023

Advertisement

Change

Revenue (In RMB million)

8,574.2

8,492.0

1.0 %

Gross Profit (In RMB million)

3,350.0

3,560.6

(5.9 %)

Margin (%)

Advertisement

39.1 %

41.9 %

Net Profit (In RMB million)

1,780.3

2,337.9

(23.9 %)

Margin (%)

20.8 %

27.5 %

Net Profit Attributable to Owners of the
Company (In RMB million)

Advertisement

1,499.1

2,266.7

(33.9 %)

Margin (%)

17.5 %

26.7 %

Adjusted Net Profit (In RMB million)

2,544.8

2,925.6

(13.0 %)

Advertisement

Margin (%)

29.7 %

34.5 %

EBITDA (In RMB million)

2,805.9

3,230.6

(13.1 %)

Margin (%)

32.7 %

38.0 %

Advertisement

Adjusted EBITDA (In RMB million)

3,570.4

3,818.3

(6.5 %)

Margin (%)

41.6 %

45.0 %

Adjusted Diluted EPS (In RMB)

0.52

0.65

Advertisement

(20.0 %)

~ End ~

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2024, WuXi Biologics is supporting 742 integrated client projects, including 16 in commercial manufacturing (excluding 8 COVID CMO projects and 1 non-COVID dormant CMO project).

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com

Forward-Looking Statements

This announcement may contain certain “forward-looking statements” that are not historical facts, but instead are predictions about future events based on our expectations as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, and our ability to protect our clients’ intellectual property. Our forward-looking statements in this announcement speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section.

Non-IFRS Measures 

Advertisement

To supplement the Group’s condensed consolidated financial statements which are presented in accordance with the IFRS, the Company has provided adjusted net profit, adjusted net profit margin, adjusted EBITDA, adjusted EBITDA margin and adjusted basic and diluted earnings per share as additional financial measures, which are not required by, or presented in accordance with, the IFRS.

The Company believes that the adjusted financial measures are useful for understanding and assessing underlying business performance and operating trends, and that the Company’s management and investors may benefit from referring to these adjusted financial measures in assessing the Group’s financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and/or non-operating items that the Group does not consider indicative of the performance of the Group’s core business. These non-IFRS financial measures, as the management of the Group believes, is widely accepted and adopted in the industry in which the Group is operating in. However, the presentation of these non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with the IFRS. Shareholders of the Company and potential investors should not view the adjusted results on a stand-alone basis or as a substitute for results under IFRS. And these non-IFRS financial measures may not be comparable to similarly-titled measures represented by other companies.

View original content:https://www.prnewswire.co.uk/news-releases/wuxi-biologics-reports-solid-2024-interim-results-302227674.html

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

Global focus on vocational education at Tianjin conference

Published

on

global-focus-on-vocational-education-at-tianjin-conference

BEIJING, Nov. 22, 2024 /PRNewswire/ — A report from China Daily

The 2024 World Vocational and Technical Education Development Conference brought together around 1,000 delegates in Tianjin in North China this week from Wednesday to Friday. Discussions at the conference have revolved around topics such as industry-education integration, sustainable development, teacher training and lifelong learning.

Co-hosted by China’s Ministry of Education, the National Commission of the People’s Republic of China for UNESCO and the Tianjin municipal government, the conference aims to advance vocational education as a driver of innovation and sustainable development worldwide.

The event introduces six key initiatives to shape vocational education globally: a comprehensive conference featuring keynote speeches, ministerial roundtables and bilateral talks; a global alliance uniting vocational institutions, industries and educational organizations; the presentation of the world vocational education award; an international skills competition with 42 tracks; an exhibition highlighting achievements in vocational education, intangible cultural heritage and international cooperation; and the launch of World Vocational and Technical Education, a journal produced by Tianjin University of Technology and Education.

In a video address to the conference, Stefania Giannini, assistant director-general for education at UNESCO, highlighted vocational education as a catalyst for transformation. She referenced UNESCO’s recent Recommendation on Education for Peace, Human Rights, and Sustainable Development, which emphasizes vocational education as a driver of change.

Calling for greater investment and innovation in vocational education to meet global challenges, Giannini said skills are the passport to navigating today’s complex world.

Huai Jinpeng, China’s minister of education, said vocational education should align with the trends of the times, uphold the essence of education and preserve its unique characteristics. It should anchor its development goals amid evolving opportunities and challenges, striving for innovative breakthroughs, he added.

Huai outlined a vision for vocational education as “5I” education — Inclusive, Industry-oriented, Innovative, Intelligent, and International — positioned to serve all, integrate with industries, drive innovation, embrace smart technologies and foster global cooperation.

To ensure smooth volunteer services during the conference, the Tianjin Municipal Youth League recruited 1,448 young volunteers from nine universities, including Nankai University. Their duties spanned more than 30 roles, including guest registration, conference coordination, translation, media reception and medical assistance.

Photo – https://mma.prnewswire.com/media/2565169/China_Daily.jpg

Advertisement

Cision View original content:https://www.prnewswire.co.uk/news-releases/global-focus-on-vocational-education-at-tianjin-conference-302314016.html

Continue Reading

Fintech PR

CKGSB Publishes 2024 ESG and Social Innovation Report Showcasing Progress on Driving Responsible Management Education

Published

on

ckgsb-publishes-2024-esg-and-social-innovation-report-showcasing-progress-on-driving-responsible-management-education

BEIJING, Nov. 22, 2024 /PRNewswire/ — On November 21, 2024, Cheung Kong Graduate School of Business (CKGSB) released its 2024 ESG and Social Innovation Report at its event “ESG Strategies Conference: Insights for Business Transition” hosted in Shanghai in collaboration with the European Chamber of Commerce in China, witnessed by nearly 100 ESG-minded multinational business executives.

As the second edition of the school’s English-language ESG report, this report outlines CKGSB’s achievements and progress in the past two years in promoting sustainable business practices, fostering social innovation, and offering solutions to humanity’s common challenges as part of its broader mission to lead and drive responsible business education.

It emphasizes the school’s role in reshaping the future of management education through efforts in integrating ESG factors into its research and insights, programs and courses for decision-makers, strategic partnerships and dialogues, as well as institutional practices, which in return allows it to nurture responsible business leaders for society.

“Our approach to management education is rooted in the belief that businesses can and should be a force for good,” stated Li Haitao, Dean and Dean’s Distinguished Chair Professor of Finance of CKGSB. “CKGSB remains steadfast in its mission to developing leaders who are not only successful in their business endeavors, but also mindful of their responsibilities towards society and the environment.” CKGSB Professor of Marketing Zhu Rui, who drives the school’s efforts in teaching business for good, echoed Dean Li in saying, “Our goal is to empower companies, big or small, to seamlessly integrate ESG considerations into their core strategies and operations.”

The 2024 ESG and Social Innovation Report follows the seven principles of and has been submitted to the United Nations’ Principles for Responsible Management Education (PRME), a platform designed to promote responsible management practices for the benefit of society and our planet. It is now available for download on CKGSB’s website.

Looking forward, CKGSB will continue driving progress on responsible management education and contribute to a more sustainable and equitable future.

About CKGSB

Established in Beijing in November 2002, CKGSB is China’s first privately-funded and research-driven business school. The school aims to cultivate transformative business leaders with a global vision, sense of social responsibility, innovative mindset, and ability to lead with empathy and compassion. To learn more about CKGSB, please visit: https://english.ckgsb.edu.cn/

View original content:https://www.prnewswire.co.uk/news-releases/ckgsb-publishes-2024-esg-and-social-innovation-report-showcasing-progress-on-driving-responsible-management-education-302314000.html

Advertisement
Continue Reading

Fintech PR

Inaugural International MICE Summit (IMS) Convenes to Drive Business Events Sector’s Future in Saudi Arabia, Fastest-Growing G20 MICE Market

Published

on

inaugural-international-mice-summit-(ims)-convenes-to-drive-business-events-sector’s-future-in-saudi-arabia,-fastest-growing-g20-mice-market
  • Over 1,000 global cross-industry and government leaders expected to attend three-day interactive program in one of the world’s fastest growing Meetings, Conferences, Incentives and Exhibitions (MICE) destinations. 
  • Saudi MICE market projected to expand exponentially with hallmark events such as World Expo 2030, expected to attract 40.7 million visits to KSA alone.
  • Growing demand to be accommodated by the launch of a new airline and airport expansion, 1 million square meters of expected venue space and 854,000 hotel rooms by 2030.

RIYADH, Saudi Arabia, Nov. 22, 2024 /PRNewswire/ — The inaugural International MICE Summit (IMS24) will bring together over 1,000 global leaders from the Meetings, Incentives, Conferences and Exhibitions (MICE) industry between 15-17 December at Mohammed Bin Salman Nonprofit City (MISK) in Riyadh, hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA).  

The three-day event promises to be the premier global leadership event for the MICE industry, offering innovation, economic and commercial opportunities for MICE and related tourism and travel sectors under the theme of “Expanding Horizons.” The event’s extensive programme is designed to unite MICE industry leaders, suppliers, associations, Giga-Project leaders, disruptors and international cross-industry and government leaders. Featuring plenary, panel discussions, innovation clusters, collaboration hubs, IMS24 will promise attendees a premier global platform to network, collaborate – and above all – reimagine what it means to convene in today’s global environment.

“In a time marked by profound technological and environmental transformation, the MICE industry has emerged as an essential catalyst of change. By focusing on the future of the industry, IMS24 addresses the needs of a globalized world – reshaping how people, cultures and countries connect to create prosperity” said IMS host and Chairman of SCEGA, His Excellency Fahd Al-Rasheed. 

 “Saudi Arabia is the perfect environment to host IMS24. As an internal and external agent of change, the Kingdom has embraced its own transformation by shaping the future of the global tourism industry and becoming the fastest growing major MICE destination among G20 countries,” His Excellency added.

MICE events in Saudi Arabia witnessed an increase of close to 15 percent in 2023, with almost 17,000 events attracting over 20 million visitors. IMS24 coincides with the Kingdom’s continued transformation as Saudi Arabia solidifies itself as a major global tourism and events destination. Welcoming almost 110 million visitors in 2023, tourism comprises six percent of Saudi Arabia’s GDP, equating to 255 billion SAR (US$68 billion). The Saudi MICE sector is expected to accelerate growth through the rapid expansion of transportation and event infrastructure, supported by the development of Giga-projects offering unparalleled destination experiences, and enhanced connectivity between the Kingdom and the rest of the world. SCEGA continues to drive these transformative developments, most recently in announcing a 588 million SAR (US$156 million) incentive program to support marquee events in 2025.

About the International MICE Summit

The International MICE Summit (IMS) gathers global leaders from the Meetings, Incentives, Conferences, and Exhibitions (MICE) sector, as well as professionals, and organizations from across industries. It provides a platform for industry insights, networking, and discussions on advancing innovation, knowledge sharing and sustainable development within the global MICE sector.

For more information or to register for the event, visit:

Website – www.internationalmicesummit.com
Twitter/X – https://x.com/ims_summit
LinkedIn – https://www.linkedin.com/company/ims-summit/
YouTube – https://youtube.com/@ims.summit?si=G06nYTaOUWer-OKq 

About the Saudi Conferences and Exhibitions General Authority (SCEGA)

The Saudi Conventions & Exhibitions General Authority (SCEGA) is the official body overseeing the development and regulation of Saudi Arabia’s exhibitions and conventions sector. Established by Royal Decree in 2018, SCEGA aims to strengthen the sector’s economic impact by setting strategic policies, issuing licenses, promoting Saudi Arabia as a premier MICE destination, and fostering investment in line with global standards. Through collaboration with national and international stakeholders, SCEGA works to enhance sector growth, support talent development, and create opportunities for showcasing the Kingdom’s unique identity on the world stage.

Advertisement

Contact: [email protected]

 

Photo – https://mma.prnewswire.com/media/2564659/SCEGA.jpg
Logo – https://mma.prnewswire.com/media/2564658/International_MICE_Summit_Logo.jpg

 

International MICE Summit Logo

 

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/inaugural-international-mice-summit-ims-convenes-to-drive-business-events-sectors-future-in-saudi-arabia-fastest-growing-g20-mice-market-302313160.html

Continue Reading

Trending